133267-79-5

Basic information

• Product Name: ((S)-8-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE
• Synonyms: ((S)-8-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE;(S)-8-METHOXY-N-PROPYL-2-AMINOTETRALINE HYDROCHLORIDE;2-NAPHTHALENAMINE, 1,2,3,4-TETRAHYDRO-8-METHOXY-N-PROPYL-, HYDROCHLORIDE, (S)-
• CAS NO: 133267-79-5
• Molecular Formula: C14H22ClNO
• Molecular Weight: 219.32
• Mol File: 133267-79-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ((S)-8-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: ((S)-8-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE(133267-79-5)
• EPA Substance Registry System: ((S)-8-METHOXY-1,2,3,4-TETRAHYDRO-NAPHTHALEN-2-YL)-PROPYL-AMINE HYDROCHLORIDE(133267-79-5)

Safety Data

• Hazardous Substances Data: 133267-79-5(Hazardous Substances Data)

Upstream product

• 5309-19-3 8-methoxy-2-tetralone 
• 107-10-8 propylamine 
• 3902-22-5 8-methoxy-2-(propylamino)-1,2,3,4-tetrahydronaphthalene 

Relevant articles and documents

Synthesis of Pharmaceutically Relevant 2-Aminotetralin and 3-Aminochroman Derivatives via Enzymatic Reductive Amination

2-Aminotetralin and 3-aminochroman derivatives are key structural motifs present in a wide range of pharmaceutically important molecules. Herein, we report an effective biocatalytic approach towards these molecules through the enantioselective reductive coupling of 2-tetralones and 3-chromanones with a diverse range of primary amine partners. Metagenomic imine reductases (IREDs) were employed as the biocatalysts, obtaining high yields and enantiocomplementary selectivity for >15 examples at preparative scale, including the precursors to Ebalzotan, Robalzotan, Alnespirone and 5-OH-DPAT. We also present a convergent chemo-enzymatic total synthesis of the Parkinson's disease therapy Rotigotine in 63 % overall yield and 92 % ee.

New aminotetraline derivatives

The present application relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds in producing medi

METHOD OF INHIBITING GASTRIC ACID SECRETION

The present invention provides a method of inhibiting gastric acid secretion in mammals by administering a 5-HT1A agonist compound or a pharmaceutically acceptable salt thereof.